<DOC>
	<DOCNO>NCT00032123</DOCNO>
	<brief_summary>RATIONALE : Biological therapy erlotinib may interfere growth tumor cell slow growth tumor . PURPOSE : Phase II trial study effectiveness erlotinib treat patient locally advance metastatic stomach cancer cancer gastroesophageal junction .</brief_summary>
	<brief_title>Erlotinib Treating Patients With Locally Advanced Metastatic Stomach Cancer Gastroesophageal Junction Cancer</brief_title>
	<detailed_description>OBJECTIVES : - Determine overall response rate patient locally advance metastatic adenocarcinoma stomach gastroesophageal junction treat erlotinib . ( Gastric stratum temporarily close accrual 03/01/2003 . ) - Determine frequency severity toxic effect drug patient . - Determine overall survival time treatment failure patient treat drug . - Determine value intratumoral expression epidermal growth factor receptor predict patient response drug . OUTLINE : This multicenter study . Patients stratify accord cancer site ( stomach v gastroesophageal junction ) . ( The gastric stratum temporarily close accrual 03-01-2003 . ) Patients receive oral erlotinib daily . Courses repeat every 28 day absence disease progression unacceptable toxicity . Patients follow every 6 month 3 year . PROJECTED ACCRUAL : A total 40-80 patient ( 20-40 per stratum ) accrue study within 14-40 month . ( The gastric stratum temporarily close accrual 03-01-2003 . )</detailed_description>
	<mesh_term>Adenocarcinoma</mesh_term>
	<mesh_term>Stomach Neoplasms</mesh_term>
	<mesh_term>Esophageal Neoplasms</mesh_term>
	<mesh_term>Erlotinib Hydrochloride</mesh_term>
	<criteria>DISEASE CHARACTERISTICS : Histologically cytologically confirm adenocarcinoma stomach* gastroesophageal ( GE ) junction GE junction tumor include esophageal tumor arise 5 cm anatomic GE junction gastric cardia Locally advance ( i.e. , unresectable ) metastatic disease NOTE : *Gastric stratum temporarily close accrual 03/01/2003 Unidimensionally measurable disease Target lesion must previously irradiate field unless documentation clear progression No known brain metastasis PATIENT CHARACTERISTICS : Age : Not specify Performance status : Zubrod 01 Life expectancy : Not specify Hematopoietic : Absolute neutrophil count least 1,500/mm^3 Platelet count least 100,000/mm^3 Hepatic : Bilirubin great 1.5 time upper limit normal ( ULN ) SGOT SGPT great 1.5 time ULN ( 5 time ULN liver metastasis present ) Renal : Creatinine great 2 time ULN Cardiovascular : No recent myocardial infarction No unstable angina No lifethreatening arrhythmia Gastrointestinal : No gastrointestinal tract disease result inability take oral medication requirement IV alimentation No active peptic ulcer disease Must able swallow and/or receive enteral medication via gastrostomy feed tube No intractable nausea vomit Ophthalmic : No history corneal disease , include : Dry eye syndrome Sj√∂gren 's syndrome Keratoconjunctivitis sicca Exposure keratopathy Fuch 's dystrophy Other active disorder cornea Other : HIV negative No active uncontrolled infection No malignancy within past 5 year except adequately treat basal cell squamous cell skin cancer , carcinoma situ cervix , adequately treated stage I II cancer currently complete remission No severe psychiatric disorder Not pregnant nursing Fertile patient must use effective contraception PRIOR CONCURRENT THERAPY : Biologic therapy : No prior biologic therapy No concurrent anticancer immunotherapy Chemotherapy : No prior chemotherapy advance metastatic gastric cancer At least 8 week since prior adjuvant chemotherapy chemotherapy give radiosensitizer recover No concurrent anticancer chemotherapy Endocrine therapy : No concurrent anticancer hormonal therapy Radiotherapy : See Disease Characteristics At least 4 week since prior radiotherapy recover No concurrent anticancer radiotherapy Surgery : At least 4 week since prior surgical procedure stomach* GE cancer recover No prior surgical procedure would affect absorption NOTE : *Gastric stratum temporarily close accrual 03/01/2003 Other : No prior investigational drug No concurrent combination antiretroviral therapy HIVpositive patient No concurrent anticancer therapy</criteria>
	<gender>All</gender>
	<minimum_age>N/A</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>October 2003</verification_date>
	<keyword>stage IV gastric cancer</keyword>
	<keyword>stage IV esophageal cancer</keyword>
	<keyword>adenocarcinoma stomach</keyword>
	<keyword>adenocarcinoma esophagus</keyword>
	<keyword>recurrent esophageal cancer</keyword>
	<keyword>recurrent gastric cancer</keyword>
</DOC>